AIDS/HIV vaccine: February 2007 Archives

geovaxATLANTA, February 05, 2007 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. , an Atlanta-based biotechnology company, today reported successful early results from two ongoing AIDS prevention Phase I human vaccine trials. Results from the first low dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving 1/10th dose of GeoVax's AIDS vaccine.

Results from a second larger full dose trial also indicate a good safety profile in participants. The GeoVax vaccines being tested are designed to prevent the development of Acquired Immunodeficiency Disease ("AIDS") caused by the virus known as HIV-1 by vaccinating individuals prior to infection with the AIDS virus.

About this Archive

This page is a archive of entries in the AIDS/HIV vaccine category from February 2007.

AIDS/HIV vaccine: January 2007 is the previous archive.

AIDS/HIV vaccine: July 2007 is the next archive.

Find recent content on the main index or look in the archives to find all content.

July 2007: Monthly Archives


Powered by Movable Type 4.24-en